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Abstract
Aims Heart failure with reduced ejection fraction (HFrEF) induces skeletal muscle mitochondrial abnormalities that contrib-
ute to exercise limitation; however, specific mitochondrial therapeutic targets remain poorly established. This study quantified
the relationship and contribution of distinct mitochondrial respiratory states to prognostic whole-body measures of exercise
limitation in HFrEF.
Methods and results Male patients with HFrEF (n = 22) were prospectively enrolled and underwent ramp-incremental cycle
ergometry cardiopulmonary exercise testing to determine exercise variables including peak pulmonary oxygen uptake
(V̇O2peak), lactate threshold (V̇O2LT), the ventilatory equivalent for carbon dioxide (V̇E/V̇CO2LT), peak circulatory power
(CircPpeak), and peak oxygen pulse. Pectoralis major was biopsied for assessment of in situ mitochondrial respiration. All
mitochondrial states including complexes I, II, and IV and electron transport system (ETS) capacity correlated with V̇O2peak
(r = 0.40–0.64; P < 0.05), V̇O2LT (r = 0.52–0.72; P < 0.05), and CircPpeak (r = 0.42–0.60; P < 0.05). Multiple regression analysis
revealed that combining age, haemoglobin, and left ventricular ejection fraction with ETS capacity could explain 52% of the
variability in V̇O2peak and 80% of the variability in V̇O2LT, respectively, with ETS capacity (P = 0.04) and complex I (P = 0.01)
the only significant contributors in the model.
Conclusions Mitochondrial respiratory states from skeletal muscle biopsies of patients with HFrEF were independently
correlated to established non-invasive prognostic cycle ergometry cardiopulmonary exercise testing indices including V̇O2peak,
V̇O2LT, and CircPpeak. When combined with baseline patient characteristics, over 50% of the variability in V̇O2peak could be
explained by the mitochondrial ETS capacity. These data provide optimized mitochondrial targets that may attenuate exercise
limitations in HFrEF.
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Introduction
Heart failure with reduced ejection fraction (HFrEF) is a com-
plex syndrome characterized by exercise intolerance and
cardiac dysfunction. The severity of symptoms and exercise
intolerance in HFrEF are most commonly assessed by the
use of both subjective patient history (e.g. NYHA
classification) and more objective laboratory-based cardiopul-
monary exercise testing (CPET). CPET is considered the
gold-standard assessment of exercise intolerance in patients
with HFrEF,1–3 providing an integrated multi-organ assess-
ment. This facilitates refined non-invasive assessment of key
indices of exercise limitation that independently predict prog-
nosis, which include peak oxygen uptake (V̇O2peak), oxygen
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uptake at the lactate threshold (V̇O2LT), and the ventilatory
equivalent for carbon dioxide at the lactate threshold
(V̇E/V̇CO2LT).
4–11
Although a defining feature of the HFrEF phenotype, the
degree of left ventricular (LV) systolic dysfunction assessed
by LV ejection fraction (LVEF) poorly correlates with the
degree of exercise intolerance.12–14 In addition, pharmaco-
logical and device interventions that improve both LVEF
and prognosis in HFrEF do not consistently improve exer-
cise tolerance.15,16 As such, a multi-organ therapeutic ap-
proach in HFrEF has been advocated, which has identified
peripheral skeletal muscle abnormalities as a key mecha-
nism of exercise intolerance in HFrEF.17–21 Collectively,
therefore, the need to clarify the relationship between
skeletal muscle abnormalities and prognostic CPET mea-
sures in HFrEF could be useful for developing tailored ther-
apeutic strategies aimed at improving exercise tolerance
and quality of life.22
Of particular interest is the major therapeutic target of
skeletal muscle mitochondrial dysfunction,23 which is pro-
posed as a fundamental mechanism underlying persistent
symptoms in HFrEF even when corresponding improve-
ments in cardiac function are observed.24 Recent techno-
logical advances provide a window for mitochondrial
function to be dynamically assessed across the electron
transport chain using muscle biopsies from patients
with HFrEF, which allows important novelty to be
gained compared with past studies where static morpholog-
ical/biochemical measures were only able to confirm global
reductions in mitochondrial content correlated to impair-
ments in V̇O2peak.
25–28 In contrast, the in situ interrogation
of permeabilized myofibres allows evaluation of distinct re-
spiratory states to identify key sites of limitation (i.e. across
the electron transport chain at multiple mitochondrial
complexes).29–31 In support, recent studies have confirmed
that mitochondrial respiration from both the upper and
lower limbs is reduced in patients with HFrEF, with
impairments to complex I being closely correlated with
V̇O2peak.
30–32 Thus far, however, a comprehensive analysis of
the relationship between mitochondrial respiratory states
and key prognostic whole-body CPET variables remains poorly
explored in HFrEF, and there is limited information about
the relative contribution of specific mitochondrial respiratory
deficits to the degree of exercise limitation.
The present study, therefore, directly assessed skeletal
muscle mitochondrial respiration from biopsies of patients
with HFrEF in order to evaluate the relationship and quan-
tify the contribution of distinct respiratory complex states
to whole-body prognostic CPET variables. We reasoned that
a better understanding of the association between distinct
mitochondrial deficits and whole-body exercise variables
would optimize future targets for attenuating symptoms re-
lated to exercise intolerance in HFrEF.
Methods
Participants
We approached consecutive patients with stable signs and
symptoms of chronic heart failure (>3 months receiving med-
ical therapy) that were untrained but ambulatory, and pre-
sented with a LVEF <50% measured by two-dimensional
echocardiography by Simpson’s biplane following current
guidelines33 who were listed for a cardiac implantable
electronic device at Leeds Teaching Hospitals NHS Trust, as
described in full details elsewhere.30 Participants were indi-
cated for device therapy with either a pacemaker, implantable
cardioverter defibrillator, or cardiac resynchronization ther-
apy device according to current indications.33 Exclusion
criteria for participation in the present study included the in-
ability to provide informed consent due to cognitive dysfunc-
tion or the presence of comorbidities potentially confounding
assessment of exercise intolerance such as other cardiovascu-
lar conditions, chronic obstructive pulmonary disease, or
ongoing malignancy or limiting musculoskeletal disease. All
patients provided written informed consent, and all proce-
dures were conducted in accordance with the Declaration
of Helsinki after receiving local institute ethical approval
(11/YH/0291). The patients included in this study are a subset
of those on whom we have previously published other
outcomes.30–32
Cardiopulmonary exercise test
Cardiopulmonary exercise testing data for patients were ob-
tained from a peak symptom-limited CPET conducted as part
of routine clinical care, continued to volitional intolerance on
a cycle ergometer for determination of V̇O2peak, V̇O2LT, peak
circulatory power (CircPpeak), and peak oxygen (O2) pulse,
RERpeak, and V̇E/V̇CO2LT. After a 5-min warm-up at 10 W,
the patients started cycling at 20 W and workload was pro-
gressively increased by 5 W min1 until the patients reached
volitional intolerance. Ventilatory and pulmonary gas ex-
change variables were collected as 15 s averages on a
breath-by-breath basis using a calibrated system (Ultimo
CardO2, Medical Graphics, St. Paul, MN, USA). V̇O2peak and
RERpeak were recorded as the highest 15 s average, while
V̇O2LT was calculated using the V-slope method, which also
allowed V̇E/V̇CO2LT to be determined.
34 In the instance when
a patient did not achieve lactate threshold and/or we were
unable to estimate lactate threshold (n = 10), the V̇O2LT and
V̇E/V̇CO2LT were not included in the analysis. CircPpeak was
defined as the product of V̇O2peak and peak systolic blood
pressure35–38 whereas peak O2 pulse was calculated as
V̇O2peak divided by heart rate peak. Patients removed the
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mouthpiece at the end of the test during recovery due to
discomfort; VO2 and VCO2 recovery half time are therefore
not reported.
Muscle biopsy
Skeletal muscle biopsy of the pectoralis major (~50 mg) was
obtained during the routine device implantation procedures
as previously described,30 which took place within one month
of baseline clinical data collection. There were no complica-
tions or adverse events with this procedure. A portion of
muscle tissue was immediately placed in 1 mL of ice-cold spe-
cialized preservation solution (BIOPS) for subsequent assess-
ment of mitochondrial respiration.31 Recent evidence from
patients with HFrEF indicate sampling of the upper limb mus-
cles provide an opportunity to investigate the disease’s sys-
temic myopathy, with the pectoralis major providing a close
surrogate for the vastus lateralis in terms of mitochondrial
function and closely linked to whole-body exercise intoler-
ance that is not as impacted by other confounding factors
(e.g. disuse, detraining, or arthritis).30 Furthermore, muscle
mass of the pectoralis major is also a powerful predictor of
prognosis in HFrEF39 and in relation to daily activities, the
upper limbs typically perform various tasks (e.g. house
chores and gardening) that would pose exercise limitations
impacting patient quality of life. As such, the clinical rele-
vance for sampling the pectoralis major in terms of exercise
limitations and prognosis is well supported.
Mitochondrial function
Mitochondrial respiration was measured in situ from
saponin-permeabilized skeletal muscle fibres using
high-resolution respirometry (Oxygraph-2K; Oroboros Instru-
ments, Innsbruck, Austria) as previously described
elsewhere.30–32 Briefly, the following steps were performed
including (i) Complex I leak respiration was determined by
addition of glutamate (10 mM), malate (0.5 mM), and
pyruvate (5 mM) (i.e. a measure of proton leak under non-
phosphorylating conditions); (ii) adenosine diphosphate
(2.5 mM) was added to stimulate oxidative phosphorylation
through Complex I (OXPHOS PI); (iii) outer mitochondrial
membrane integrity was determined by addition of 10 μM
cytochrome c; (iv) succinate at 10 mM to stimulate Complex
I + II (OXPHOS PI + II); (v) 0.5 μM titrations of FCCP to
achieve maximal uncoupled respiration for electron
transport system (ETS) capacity; (vi) Complex I inhibitor
rotenone at 0.25 μM for ETS-supported Complex II
respiration (CII); (vii) 2.5 μM antimycin A as a Complex III
inhibitor for residual oxygen consumption (ROX) to calculate
non-mitochondrial (background) respiration, which was
subtracted from all values. Complex IV respiration (CIV) was
also measured by the addition of 0.5 mM TMPD and 2 mM
ascorbate.40 Values for mitochondrial respiration were
normalized to muscle wet mass and are presented as pmol
O2/s/mg.
Statistical analysis
Bivariate associations between mitochondrial and CPET vari-
ables were examined by Pearson’s correlations coefficients.
Multiple regression analysis was carried out to determine
the independent contributors of V̇O2peak variability. In a first
step, variables with an established physiological role in
V̇O2peak including age, haemoglobin concentration (Hb), and
LVEF were entered as a block to a multivariable regression
model to determine how much of the variability in V̇O2peak
could be explained by these variables.41–43 We then ran the
same model combined with each mitochondrial complex
separately to quantify the contribution of each complex by
explaining V̇O2peak variability. If any of the r
2 value was
greater than 0.75 and thus the variance inflation factor
greater than 4.0, we considered multicollinearity might be a
problem, but this was not the case in the present analysis.
Statistical significance was accepted as P < 0.05. Data are
presented as mean ± standard deviation. All statistical analy-
ses were performed using GraphPad Prism version 9.0.0.
Results
Patient population
Patient characteristics and medications are shown in Table 1,
while CPET data are shown in Table 2.
Correlation between mitochondrial respiration
and cardiopulmonary exercise testing variables
We first assessed the correlation between key patient physi-
cal and clinical variables with CPET measures. There were no
correlations (P > 0.05) between age, Hb, and LVEF with
V̇O2peak or other CPET variables, although Hb showed a strong
trend with V̇O2peak (r = 0.38; P = 0.08). In contrast, peripheral
skeletal muscle mitochondrial function of the pectoralis major
was well correlated with various whole-body CPET variables
(Table 3). Figure 1 displays the correlations between stimu-
lated mitochondrial respiratory states and the most common
measure of exercise intolerance: V̇O2peak. Mitochondrial
respiration of complex I, complex I + II and ETS capacity corre-
lated with V̇O2peak (range: r = 0.49–0.64 and P< 0.01; Table 3
and Figure 1A–C), whereas complexes II and IV did not
correlate (Table 3; Figure 1D–E).
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We next assessed the correlation between mitochondrial
respiration and another key CPET-derived measure of aerobic
performance and prognosis in HFrEF: the V̇O2LT (Figure 2). Mi-
tochondrial respiratory complexes I, I + II, and IV and ETS ca-
pacity were all correlated with V̇O2LT (range: r = 0.60–0.71
and P < 0.05; Table 3 and Figure 2A–E), whereas complex II
did not (P = 0.084; Table 3 and Figure 2D). In addition to
V̇O2peak and V̇O2LT, the V̇E/V̇CO2LT is another strong predictor
of prognosis in HFrEF that is thought to be independent of ef-
fort. As opposed to V̇O2peak and V̇O2LT, we did not observe
correlations across mitochondrial respiratory complexes with
V̇E/V̇CO2LT (P > 0.05; Table 3) or with another variable that is
commonly used to indicate maximal effort: RERpeak (P> 0.05;
Table 3). While the peak O2 pulse also showed no correla-
tions (P > 0.05; Table 3), we found CircPpeak was correlated
across most mitochondrial respiratory complexes (range:
r = 0.42–0.60 and P < 0.05; Table 3). An overview of the de-
gree of correlation between invasive skeletal muscle mito-
chondrial measures and non-invasive whole-body
performance CPET variables is presented in Figure 3, with
Table 1 Clinical variables of patients with heart failure with
reduced ejection fraction (n = 22)
Demographics
Age (years) 69 ± 12
Male sex [n(%)] 22 (100)
BMI (kg/m2) 28.5 ± 4.0
NYHA Class III/IV [n(%)] 5 (23)
Aetiology of HF
Ischaemic [n(%)] 9 (41)
DCM [n(%)] 6 (27)
Past medical history
Diabetes mellitus [n(%)] 6 (27)
AF [n(%)] 11 (50)
COPD [n(%)] 1 (5)
Hypertension [n(%)] 10 (45)
Device therapy
PPM [n(%)] 3 (14)
ICD [n(%)] 4 (18)
CRT [n(%)] 15 (68)
Medications
Antiplatelet [n(%)] 11 (50)
Beta-blocker [n(%)] 18 (82)
ACE-I/ARB [n(%)] 18 (82)
Loop diuretic [n(%)] 11 (50)
MRA [n(%)] 11 (50)
Statin [n(%)] 16 (73)
Anticoagulant [n(%)] 8 (36)
Metformin [n(%)] 4 (18)
Insulin [n(%)] 2 (9)
Echocardiogram
LVEF (%) 31.7 ± 13.9
LVEDd (mm) 58.1 ± 7.1
PASP (mmHg) 33.6 ± 15.9
Laboratory investigations
Hb (g/L) 140.8 ± 15.4
Creatinine (μmol/L) 98.5 ± 24.1
HbA1c (mmol/mol) 45.1 ± 11.1
Normally distributed continuous variables are expressed as
mean ± standard deviation; discrete variables are presented as
number and percentages in parentheses. ACE-I, angiotensin
converting enzyme inhibitor; ARB, angiotensin II receptor blocker;
BMI, body mass index; CHF, chronic heart failure; COPD, chronic
obstructive pulmonary disease; CRT, cardiac resynchronisation
therapy; DCM, dilated cardiomyopathy; Hb, haemoglobin; HbA1c,
glycated haemoglobin; ICD, implantable cardioverter defibrillator;
LVED, left ventricular end-diastolic diameter; LVEF, left ventricular
ejection fraction; MRA, mineralocorticoid receptor blocker; NT-
pro-BNP, N-terminal pro brain natriuretic peptide; NYHA, New York
Heart Association; PASP, pulmonary artery systolic pressure; PPM,
permanent pacemaker.
Table 2 Exercise variables for patients with heart failure with
reduced ejection fraction
CPET variable Mean ± SD
V̇O2peak (mL/kg/min) 16.7 ± 4.9
V̇O2LT (mL/kg/min) 12.6 ± 4.9
CircPpeak (mmHg × mL/kg/min) 2435 ± 863
Peak O2 Pulse (mL/beat) 11.9 ± 5.5
RERpeak 1.1 ± 0.2
VE/VCO2LT 32.2 ± 6.1
SBPpeak (mmHg) 143.1 ± 22.4
DBPpeak (mmHg) 72.0 ± 8.8
HRpeak (bpm) 120.1 ± 21.6
CPET, cardiopulmonary exercise testing; peak O2 pulse, peak oxy-
gen pulse; CircPpeak, peak circulatory power; RERpeak, respiratory
exchange ratio at V̇O2peak; V̇E/V̇CO2LT, ventilation and carbon diox-
ide production ratio at lactate threshold; V̇O2peak, peak oxygen up-
take; V̇O2LT, lactate threshold.
Table 3 Correlations between pectoralis major mitochondrial
respiratory states and cardiopulmonary exercise testing variables,
including r, r2 and level of significance
PI PI + II ETS CII CIV
V̇O2peak
r 0.58 0.54 0.64 0.49 0.40
r2 0.34 0.29 0.41 0.24 0.16
P 0.00 0.01 0.00 0.02 0.06
V̇O2LT
r 0.72 0.71 0.70 0.52 0.60
r2 0.52 0.49 0.49 0.27 0.36
P 0.01 0.01 0.01 0.08 0.04
CircPpeak
r 0.60 0.56 0.54 0.42 0.49
r2 0.36 0.31 0.29 0.18 0.25
P 0.01 0.02 0.02 0.08 0.04
Peak O2 pulse
r 0.25 0.11 0.31 0.17 0.29
r2 0.06 0.01 0.09 0.28 0.08
P 0.36 0.69 0.25 0.53 0.28
RERpeak
r 0.09 0.25 0.12 0.06 0.18
r2 0.00 0.06 0.01 0.00 0.03
P 0.76 0.38 0.68 0.84 0.54
V̇E/V̇CO2LT
r 0.15 0.21 0.24 0.48 0.21
r2 0.02 0.04 0.06 0.23 0.04
P 0.64 0.51 0.45 0.12 0.52
CircPpeak, peak circulatory power; CII, ETS-supported Complex II;
CIV, Complex IV; ETS, electron transport system capacity; RERpeak,
respiratory exchange ratio at V̇O2peak; V̇E/V̇CO2LT, ventilation and
carbon dioxide production ratio at lactate threshold; V̇O2peak, peak
oxygen uptake; V̇O2LT, lactate threshold; peak O2 pulse, peak
oxygen pulse; PI, OXPHOS Complex I; PI + II, OXPHOS complex; r, r
correlation; r2, r squared; P, P value.
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the strongest relationships found between the mitochondrial
respiratory states of ETS capacity and complex I with V̇O2peak
and V̇O2LT, respectively.
Multiple regression analysis
A multiple regression was performed with the baseline pa-
tient variables including age, Hb, LVEF as one block and
alongside each mitochondrial respiratory state in the
pectoralis major to predict the variability in determining
whole-body V̇O2peak and V̇O2LT. Patient characteristics of
age, Hb, and LVEF could explain 24% of the variability in
V̇O2peak; however, the model or one of the contributors did
not reach statistical significance. Figure 4A demonstrates
the r2 value and level of significance for the model combined
with each individual mitochondrial complex. Overall, the
model that included age, Hb, LVEF, and ETS capacity was able
to explain 52% of the variability in V̇O2peak (r
2 0.52; P = 0.01).
From all mitochondrial variables, ETS capacity and complex I
Figure 1 Correlations between mitochondrial respiratory states and whole-body V̇O2peak. PI, OXPHOS complex I; PI + II, OXPHOS complex; ETS, maximal
electron transport system capacity; CII, ETS-supported complex II; CIV, complex IV.
Figure 2 Correlations between mitochondrial respiratory states and lactate threshold (V̇O2LT). CII, ETS-supported Complex II; CIV, Complex IV; ETS, max-
imal electron transport system capacity; PI, OXPHOS Complex I; PI + II, OXPHOS complex.
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were the only independent variables that reached statistical
significance while all others resulted in a lower prediction
of V̇O2peak (range: 30–50% and P > 0.05; Figure 4A). In addi-
tion, mitochondrial complex I respiration explained 80% of
the variability in V̇O2LT (r
2 0.80 and P = 0.01; Figure 4B) and
complex IV 72% (r2 0.72 and P = 0.04; Figure 4B), while the
other individual mitochondrial complexes did not reach sta-
tistical significance.
Discussion
We confirm that invasive measurements of mitochondrial
respiration from skeletal muscle biopsies of patients with
HFrEF independently correlate with standard non-invasive
clinical CPET variables that are commonly used to assess
exercise limitation and prognosis. We show that measures
of mitochondrial respiration under a range of stimulated
conditions (i.e. complexes I, II, and IV and ETS capacity) were
correlated with V̇O2peak, V̇O2LT, and CircPpeak. In contrast,
other important prognostic CPET-derived indices such as
peak O2 pulse, V̇E/V̇CO2LT and indicators of maximal effort
(i.e. RERpeak) showed no clear relationship. Importantly, when
combined with baseline patient characteristics, mitochondrial
ETS capacity could explain at least 50% of the variability in
V̇O2peak (i.e. one of the strongest measures of exercise limita-
tion and prognosis in HFrEF). Overall, therefore, our findings
suggest that therapies targeting specific limitations in mito-
chondrial respiration related to ETS capacity could benefit
Figure 3 Heat map showing intensity of correlation between mitochondrial respiratory states and whole-body cardiopulmonary exercise testing
(CPET) variables.
Figure 4 Bar chart demonstrating the percentage V̇O2peak (A) and V̇O2LT (B) explained by individual mitochondrial complexes combined with age, Hb
and LVEF. *P < 0.05 for analysis of variance, such that independent variables significantly predict V̇O2peak.
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whole-body exercise tolerance and prognosis in patients
with HFrEF.
Is mitochondrial function linked to
cardiopulmonary exercise testing variables in
heart failure with reduced ejection fraction?
Exercise tolerance depends on the succession of several steps
in the oxygen delivery-utilization cascade from lungs, heart,
and vasculature to skeletal muscle mitochondria,44 which is
most commonly quantified using CPET42 where key exercise
variables that include V̇O2peak, V̇O2LT, and V̇E/V̇CO2LT strongly
predict mortality.4 Mitochondrial abnormalities in peripheral
skeletal muscle are a major mechanism limiting whole-body
V̇O2peak in patients with HFrEF.
17–21 Surprisingly few studies
have provided a comprehensive assessment of the relation-
ship between mitochondrial function and prognostic CPET
variables to delineate mitochondrial-specific impairments vs.
CPET indices beyond V̇O2peak. We hypothesized that careful
examination of the relationships between invasive mitochon-
drial and whole-body CPET variables would provide impor-
tant insight for understanding markers of exercise limitation
and prognosis in HFrEF.
It has previously been shown that static measures of mito-
chondrial content and morphology are correlated to VO2peak
in patients with HFrEF.25–28 Here we uniquely developed this
line of enquiry by examining the contribution of dynamic mi-
tochondrial respiration across complexes I, II, and IV and ETS
in skeletal muscle to prognostic measures of exercise limita-
tion in patients with HFrEF. Recent detailed assessments of
mitochondrial respiration in situ have confirmed oxygen flux
is lower in patients with HFrEF.30–32 Impairments to mito-
chondrial content rather than intrinsic function have been
suggested to play the dominant role, with complexe I and
IV dysfunction being closely correlated to V̇O2peak.
30–32 Earlier
studies using more static measurements of mitochondrial
function (e.g. in vitro enzyme activity or protein content)
have also found lower values in patients with HFrEF that cor-
related to V̇O2peak,
25,26 but findings have been inconsistent in
both humans45 and animals.46,47 However, beyond the
V̇O2peak, relatively little information has been gleaned from
other CPET measures and their relationship to mitochondrial
function in HFrEF. This has limited insights into whether mito-
chondrial abnormalities in HFrEF could also be contributing to
other prognostic CPET markers. Here we clearly show that
multiple mitochondrial respiration states (e.g. complexes I,
II, and IV and ETS) were correlated to the key CPET parame-
ters of V̇O2LT and V̇O2peak, but not to the ventilatory prognos-
tic marker of V̇E/V̇CO2LT. The reason for this is likely explained
by both V̇O2LT and V̇O2peak being dictated, in large part, by
the degree of oxygen utilization (and thus mitochondrial
function), while V̇E/V̇CO2LT being more closely linked to pul-
monary/acid–base balance coupling.48 What is clear is that
interventions to improve V̇O2peak in patients with HFrEF are
frequently associated with improvements in prognosis: for
example, exercise training in patients with HFrEF reverses
skeletal mitochondrial abnormalities in parallel to improved
V̇O2peak and prognosis.
49–51
One intriguing question, therefore, is whether improving
skeletal muscle mitochondrial respiration alone would
increase V̇O2LT and V̇O2peak in patients with HFrEF, thereby
improving symptoms and prognosis? Rodent models that
inherit a genetically high V̇O2peak are known to have higher
levels of mitochondrial function in skeletal muscle, and these
are linked to reduced development of cardiometabolic
disease and improved survival rates.52 Thus, these data
support the concept that maintaining high ‘mitochondrial
fitness’ in skeletal muscle would likely benefit both measures
of exercise tolerance and prognosis in patients with HFrEF.
The contribution of mitochondrial function to
exercise limitation in heart failure with reduced
ejection fraction
Improving our understanding of the primary factors limiting
exercise tolerance in HFrEF will facilitate the identification
of more targeted mechanisms and the advent of more
effective treatments. Our study and work by others clearly
highlight a close relationship between skeletal muscle mito-
chondrial dysfunction and whole-body exercise tolerance in
HFrEF.17–21 However, this study provides further information
by using experimental evidence to predict the distinct intrin-
sic mitochondrial characteristics and their contribution
towards the degree of exercise intolerance developed in
HFrEF. Here, our findings of the monovariate analysis add
new evidence by demonstrating that mitochondrial function
under various respiratory states (e.g. PI, PI + II, and ETS) con-
tributes around 50% and 35% to the variability in VO2LT and
VO2peak in HFrEF, respectively. Given that V̇O2peak and V̇O2LT
are influenced by other key factors such as cardiac output,
blood flow distribution, and oxygen diffusion,44 the fact that
skeletal muscle mitochondrial function does not entirely ex-
plain all the variance in whole-body V̇O2peak and V̇O2LT is
not surprising.
To provide further evidence we also performed a multivar-
iate regression analysis that included key patient characteris-
tics (e.g. age, Hb, and LVEF), which demonstrated that 52% of
the variability in V̇O2peak in HFrEF was related to mitochon-
drial ETS capacity (vs. 41% at the monovariate level). Interest-
ingly only mitochondrial ETS capacity was independently
correlated to V̇O2peak in the multivariate analysis and not
other respiratory states. These data indicate, therefore, that
mitochondrial ETS capacity should be considered one major
target for future skeletal muscle mitochondrial therapies in
HFrEF, as this would likely achieve the greatest benefits to
whole-body exercise tolerance. The unexplained variance in
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the model is likely explained by other factors, including
inter-individual pathophysiological differences related to the
O2 delivery-utilization cascade related to skeletal muscle,
cardiac and pulmonary mechanisms.
Recent data from a larger cohort of patients with HFrEF
have also shown that training status and smoking history
can further play a role in explaining the V̇O2peak variability.
53
Indeed, impaired peripheral vascular function is also touted
not only to play a major role in causing severe exercise limi-
tations in patients with HFrEF, but as a potentially important
upstream mechanism that could mediate severe mitochon-
drial derangements (i.e. by reducing oxygen delivery via
endothelial dysfunction and/or capillary rarefaction).44 As
such, we acknowledge that mitochondrial respiration cannot
entirely explain V̇O2peak variability in HFrEF patients and more
research is needed to elucidate other contributing mecha-
nisms using larger sample sizes. Yet, our findings could con-
tribute to better understanding what specific mechanisms
allow patients with HFrEF to increase their V̇O2peak following
exercise training given the wide variability typically observed,
as recently reviewed in detail.54
Conclusion
Invasive measurements of mitochondrial respiratory states
fromskeletalmuscle biopsies of patientswithHFrEFwere inde-
pendently correlated to key non-invasive CPET measures of
exercise limitation and prognosis that included V̇O2peak, V̇O2LT,
and CircPpeak, but not V̇E/V̇CO2LT, peak O2 pulse or RERpeak.
When combined with other patient variables, at least 50% of
the variability in V̇O2peak could be explained by the mitochon-
drial ETS capacity. Overall, these data expand our knowledge
on specific mitochondrial targets in the skeletal muscle that
may help alleviate symptoms of exercise intolerance in HFrEF.
Acknowledgements
We thank Dr Jack Garnham for excellent technical assistance.
C. F. is supported by the British Heart Foundation (BHF) Pro-
ject Grant (PG/19/3/34133). T. S. B. supported by the Medical
Research Council (MRC) UK (MR/S025472/1).
Conflict of interest
P. K. declares no conflict of interest. S. S. declares no conflict
of interest. J. G. declares no conflict of interest. A. K. declares
no conflict of interest. L. D. R. declares no conflict of interest.
K. K. W. has received speakers’ fees and honoraria from
Medtronic, Cardiac Dimensions, Novartis, Abbott, BMS,
Pfizer, Bayer, and has received unconditional research grants
from Medtronic. C. F. declares no conflict of interest.
T. S. B. declares no conflict of interest.
References
1. Ross R, Blair SN, Arena R, Church TS,
Despres JP, Franklin BA, Haskell WL,
Kaminsky LA, Levine BD, Lavie CJ,
Myers J, Niebauer J, Sallis R, Sawada
SS, Sui X, Wisloff U. Importance of
assessing cardiorespiratory fitness in
clinical practice: a case for fitness as a
clinical vital sign: a scientific statement
from the American Heart Association.
Circulation 2016; 134: e653–e699.
2. Guazzi M, Arena R, Halle M, Piepoli MF,
Myers J, Lavie CJ. 2016 Focused update:
clinical recommendations for cardiopul-
monary exercise testing data assessment
in specific patient populations. Circula-
tion 2016; 133: e694–e711.
3. Guazzi M, Bandera F, Ozemek C,
Systrom D, Arena R. Cardiopulmonary
exercise testing: what is its value? J Am
Coll Cardiol 2017; 70: 1618–1636.
4. Tan C, Rossiter HB, Porszasz J, Bowen
TS, Witte KK, Stringer WW, Casaburi R,
Hansen JE. Reliability and physiological
interpretation of pulmonary gas ex-
change by “circulatory equivalents” in
chronic heart failure. J Am Heart Assoc
2018; 7: e008072.
5. Stringer WW. Cardiopulmonary exercise
testing: current applications. Expert Rev
Respir Med 2010; 4: 179–188.
6. Wasserman K, Hansen JE, Sue D,
Stringer W, Whipp BJ. Principles of exer-
cise testing and interpretation. Fourth
Edition. Philadelphia, PA: Lippincott
Williams & Wilkins, 2005.
7. Yardley M, Havik OE, Grov I, Relbo A,
Gullestad L, Nytrøen K. Peak oxygen up-
take and self-reported physical health
are strong predictors of long-term sur-
vival after heart transplantation. Clin
Transplant 2016; 30: 161–169.
8. Brubaker PH, Berry MJ, Brozena SC,
Morley DL, Walter JD, Paolone AM,
Bove AA. Relationship of lactate and
ventilatory thresholds in cardiac trans-
plant patients. Med Sci Sports Exerc
1993; 25: 191–196.
9. Keteyian SJ, Patel M, Kraus WE,
Brawner CA, McConnell TR, Pina IL,
Leifer ES, Fleg JL, Blackburn G, Fonarow
GC, Chase PJ, Piner L, Vest M, O’Connor
CM, Ehrman JK, Walsh MN, Ewald G,
Bensimhon D, Russell SD. Variables
measured during cardiopulmonary
exercise testing as predictors of mortal-
ity in chronic systolic heart failure. J
Am Coll Cardiol 2016; 67: 780–789.
10. Gitt AK, Wasserman K, Kilkowski C,
Kleemann T, Kilkowski A, Bangert M,
Schneider S, Schwarz A, Senges J. Exer-
cise anaerobic threshold and ventilatory
efficiency identify heart failure patients
for high risk of early death. Circulation
2002; 106: 3079–3084.
11. Tomono J, Adachi H, Oshima S,
Kurabayashi M. Usefulness of anaerobic
threshold to peak oxygen uptake
ratio to determine the severity and
pathophysiological condition of chronic
heart failure. J Cardiol 2016; 68:
373–378.
12. Clark AL, Davies LC, Francis DP, Coats
AJ. Ventilatory capacity and exercise tol-
erance in patients with chronic stable
heart failure. Eur J Heart Fail 2000; 2:
47–51.
13. Franciosa JA, Park M, Levine TB. Lack of
correlation between exercise capacity
and indexes of resting left ventricular
performance in heart failure. Am J
Cardiol 1981; 47: 33–39.
8 P. Knuiman et al.
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13272
14. Witte KK, Nikitin NP, De Silva R, Cleland
JG, Clark AL. Exercise capacity and car-
diac function assessed by tissue Doppler
imaging in chronic heart failure. Heart
2004; 90: 1144–1150.
15. Franciosa JA, Cohn JN. Effect of
isosorbide dinitrate on response to sub-
maximal and maximal exercise in pa-
tients with congestive heart failure. Am
J Cardiol 1979; 43: 1009–1014.
16. Ponikowski P, Chua TP, Anker SD,
Francis DP, Doehner W, Banasiak W,
Poole-Wilson PA, Piepoli MF, Coats AJ.
Peripheral chemoreceptor hypersensitiv-
ity: an ominous sign in patients with
chronic heart failure. Circulation 2001;
104: 544–549.
17. Fülster S, Tacke M, Sandek A, Ebner N,
Tschöpe C, Doehner W, Anker SD, Von
Haehling S. Muscle wasting in patients
with chronic heart failure: results from
the studies investigating co-morbidities
aggravating heart failure (SICA-HF).
Eur Heart J 2013; 34: 512–519.
18. Harrington D, Anker SD, Chua TP,
Webb-Peploe KM, Ponikowski PP,
Poole-Wilson PA, Coats AJ. Skeletal
muscle function and its relation to exer-
cise tolerance in chronic heart failure. J
Am Coll Cardiol 1997; 30: 1758–1764.
19. Lipkin D, Jones DA, Round JM, Poole-
Wilson PA. Abnormalities of skeletal
muscle in patients with chronic heart
failure. Int J Cardiol 1988; 18: 187–195.
20. Massie B, Simonini A, Sahgal P, Wells L,
Dudley GA. Relation of systemic and lo-
cal muscle exercise capacity to skeletal
muscle characteristics in men with con-
gestive heart failure. J Am Coll Cardiol
1996; 27: 140–145.
21. Schaufelberger M, Eriksson B, Grimby G,
Held P, Swedberg K. Skeletal muscle al-
terations in patients with chronic heart
failure. Eur Heart J 1997; 18: 971–980.
22. Houstis NE, Eisman AS,
Pappagianopoulos PP, Wooster L, Bailey
CS, Wagner PD, Lewis GD. Exercise in-
tolerance in heart failure with preserved
ejection fraction: diagnosing and rank-
ing its causes using personalized O2
pathway analysis. Circulation 2018;
137: 148–161.
23. Kumar AA, Kelly DP, Chirinos JA. Mito-
chondrial dysfunction in heart failure
with preserved ejection fraction. Circu-
lation 2019; 139: 1435–1450.
24. Haykowsky MJ, Tomczak CR, Scott JM,
Paterson DI, Kitzman DW. Determinants
of exercise intolerance in patients with
heart failure and reduced or preserved
ejection fraction. J Appl Physiol 2015;
119: 739–744.
25. Drexler H, Riede U, Munzel T, Konig H,
Funke E. Just H. Alterations of skeletal
muscle in chronic heart failure. Circula-
tion 1992; 85: 1751–1759.
26. Garnier A, Fortin D, Zoll J, N’Guessan B,
Mettauer B, Lampert E, Veksler V,
Ventura-Clapier R. Coordinated changes
in mitochondrial function and biogene-
sis in healthy and diseased human skele-
tal muscle. FASEB J 2005; 19: 43–52.
27. Hambrecht R, Fiehn E, Yu J, Niebauer J,
Weigl C, Hilbrich L, Adams V, Riede U,
Schuler G. Effects of endurance training
on mitochondrial ultrastructure and fi-
ber type distribution in skeletal muscle
of patients with stable chronic heart fail-
ure. J Am Coll Cardiol 1997; 29:
1067–1073.
28. Larsen AI, Lindal S, Myreng K, Ogne C,
Kvaloy JT, Munk PS, Aukrust P,
Yndestad A, Dickstein K, Nilsen DW.
Cardiac resynchronization therapy im-
proves minute ventilation/carbon diox-
ide production slope and skeletal
muscle capillary density without rever-
sal of skeletal muscle pathology or in-
flammation. Europace 2013; 15:
857–864.
29. Pesta D, Gnaiger E. High-resolution res-
pirometry: OXPHOS protocols for hu-
man cells and permeabilized fibers
from small biopsies of human muscle.
Methods Mol Biol 2012; 810: 25–58.
30. Caspi T, Straw S, Cheng C, Garnham JO,
Scragg JL, Smith J, Koshy AO, Levelt E,
Sukumar P, Gierula J, Beech DJ, Kear-
ney MT, Cubbon RM, Wheatcroft SB,
Witte KK, Roberts LD, Bowen TS. Unique
transcriptome signature distinguishes
patients with heart failure with myopa-
thy. J Am Heart Assoc 2020; 9: e017091.
31. Garnham JO, Roberts LD, Caspi T, Al-
Owais MM, Bullock M, Swoboda PP,
Koshy A, Gierula J, Paton MF, Cubbon
RM, Kearney MT, Bowen TS, Witte KK.
Divergent skeletal muscle mitochondrial
phenotype between male and female pa-
tients with chronic heart failure. J Ca-
chexia Sarcopenia Muscle 2020; 11:
79–88.
32. Garnham JO, Roberts LD, Espino-
Gonzalez E, Whitehead A, Swoboda PP,
Koshy A, Gierula J, Paton MF, Cubbon
RM, Kearney MT, Egginton S, Bowen
TS, Witte KK. Chronic heart failure with
diabetes mellitus is characterized by a
severe skeletal muscle pathology. J Ca-
chexia Sarcopenia Muscle 2020; 11:
394–404.
33. Ponikowski P, Voors AA, Anker SD,
Bueno H, Cleland JG, Coats AJ, Falk V,
Gonzalez-Juanatey JR, Harjola VP,
Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske
B, Riley JP, Rosano GM, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer
P. 2016 ESC Guidelines for the diagnosis
and treatment of acute and chronic
heart failure: The Task Force for the di-
agnosis and treatment of acute and
chronic heart failure of the European
Society of Cardiology (ESC). Developed
with the special contribution of the
Heart Failure Association (HFA) of the
ESC. Eur J Heart Fail 2016; 18: 891–975.
34. Beaver WL, Wasserman K, Whipp BJ. A
new method for detecting anaerobic
threshold by gas exchange. J Appl Phys-
iol (1985) 1986; 60: 2020–2027.
35. Tang Y, Yao L, Liu Z, Xie W, Ma X, Luo Q,
Zhao Z, Huang Z, Gao L, Jin Q, Yu X,
Xiong C, Ni X, Yan Y, Qi W. Peak
circulatory power is a strong prognostic
factor in patients with idiopathic pulmo-
nary arterial hypertension. Respir Med
2018; 135: 29–34.
36. Cohen-Solal A, Tabet JY, Logeart D,
Bourgoin P, Tokmakova M, Dahan M. A
non-invasively determined surrogate of
cardiac power (‘circulatory power’) at
peak exercise is a powerful prognostic
factor in chronic heart failure. Eur Heart
J 2002; 23: 806–814.
37. Nicholls DP, O’Dochartaigh C, Riley MS.
Circulatory power—a new perspective
on an old friend. Eur Heart J 2002; 23:
1242–1245.
38. Tabet JY, Metra M, Thabut G, Logeart D,
Cohen-Solal A. Prognostic value of car-
diopulmonary exercise variables in
chronic heart failure patients with or
without beta-blocker therapy. Am J
Cardiol 2006; 98: 500–503.
39. Kumar A, Ansari BA, Kim J, Suri A,
Gaddam S, Yenigalla S, Vanjarapu JM,
Selvaraj S, Tamvada D, Lee J, Akers SR,
Chirinos JA. Axial muscle size as a
strong predictor of death in subjects
with and without heart failure. J Am
Heart Assoc 2019; 8: e010554.
40. Kuznetsov AV, Gnaiger E. Oxygraph as-
say of cytochrome c oxidase activity:
chemical background correction.
Mitochondr Phys Netw 2010; 6: 1–4.
41. di Prampero PE, Ferretti G. Factors limit-
ing maximal oxygen consumption in
humans. Respir Physiol 1990; 80:
113–128.
42. Bassett DR Jr, Howley ET. Limiting fac-
tors for maximum oxygen uptake and
determinants of endurance perfor-
mance. Med Sci Sports Exerc 2000; 32:
70–84.
43. Levine BD. What do we know, and what
do we still need to know? J Physiol
2008; 586: 25–34.
44. Poole DC, Hirai DM, Copp SW, Musch
TI. Muscle oxygen transport and utili-
zation in heart failure: implications
for exercise (in)tolerance. Am J Physiol
Heart Circ Physiol 2012; 302:
H1050–H1063.
45. Williams AD, Selig S, Hare DL, Hayes A,
Krum H, Patterson J, Geerling RH, Toia
D, Carey MF. Reduced exercise toler-
ance in CHF may be related to factors
other than impaired skeletal muscle oxi-
dative capacity. J Card Fail 2004; 10:
141–148.
46. Garnier A, Fortin D, Delomenie C,
Momken I, Veksler V, Ventura-Clapier
R. Depressed mitochondrial transcrip-
tion factors and oxidative capacity in
rat failing cardiac and skeletal muscles.
J Physiol 2003; 551: 491–501.
47. De Sousa E, Veksler V, Bigard X, Mateo P,
Ventura-Clapier R. Heart failure affects
mitochondrial but not myofibrillar in-
trinsic properties of skeletal muscle. Cir-
culation 2000; 102: 1847–1853.
48. Whipp BJ. Physiological mechanisms
dissociating pulmonary CO2 and O2 ex-
change dynamics during exercise in
humans. Exp Physiol 2007; 92: 347–355.
Mitochondrial function in heart failure 9
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13272
49. Cattadori G, Segurini C, Picozzi A,
Padeletti L, Anzà C. Exercise and heart
failure: an update. ESC Heart Fail 2018;
5: 222–232.
50. Flynn KE, Piña IL, Whellan DJ, Lin L,
Blumenthal JA, Ellis SJ, Fine LJ, Howlett
JG, Keteyian SJ, Kitzman DW, Kraus WE,
Miller NH, Schulman KA, Spertus JA,
O’Connor CM, Weinfurt KP, Investiga-
tors H-A. Effects of exercise training on
health status in patients with chronic
heart failure: HF-ACTION randomized
controlled trial. JAMA 2009; 301:
1451–1459.
51. Rees K, Taylor RS, Singh S, Coats AJS,
Ebrahim S. Exercise based rehabilitation
for heart failure. Cochrane Database Syst
Rev 2004: CD003331–CD003331.
52. Wisløff U, Najjar SM, Ellingsen O,
Haram PM, Swoap S, Al-Share Q,
Fernström M, Rezaei K, Lee SJ, Koch
LG, Britton SL. Cardiovascular risk fac-
tors emerge after artificial selection for
low aerobic capacity. Science 2005;
307: 418–420.
53. Karlsen T, Videm V, Halle M, Ellingsen
O, Stoylen A, Dalen H, Delagardelle C,
Larsen AI, Hole T, Mezzani A,
Craenenbroeck EMV, Beckers P, Pressler
A, Christle JW, Winzer EB, Mangner N,
Woitek FJ, Hollriegel R, Snoer M,
Feiereisen P, Valborgland T, Linke A,
Prescott E. Baseline and exercise predic-
tors of V O2 peak in systolic heart failure
patients: results from SMARTEX-HF.
Med Sci Sports Exerc 2020; 52: 810–819.
54. Gevaert AB, Adams V, Bahls M, Bowen
TS, Cornelissen V, Dörr M, Hansen D,
Kemps HM, Leeson P, Van
Craenenbroeck EM, Kränkel N. Towards
a personalised approach in exercise-
based cardiovascular rehabilitation:
How can translational research help? A
‘call to action’ from the Section on Sec-
ondary Prevention and Cardiac Rehabili-
tation of the European Association of
Preventive Cardiology. Eur J Prev Cardiol
2020; 27: 1369–1385.
10 P. Knuiman et al.
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13272
